We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$142M
1-Year Est. Return
783.79%
This Fund
S&P 500
This Quarter
Est. Return
-0.23%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$238M
AUM Growth
-$45.5M
(-16%)
Cap. Flow
-$26.2M
Cap. Flow
% of AUM
-11.03%
Top 10 Holdings %
Top 10 Hldgs %
62.29%
Holding
58
New
11
Increased
7
Reduced
11
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$18.1M |
| 2 |
Relmada Therapeutics
RLMD
|
+$8.98M |
| 3 |
Pyxis Oncology
PYXS
|
+$7.76M |
| 4 |
Aldeyra Therapeutics
ALDX
|
+$3.81M |
| 5 |
Viridian Therapeutics
VRDN
|
+$3.39M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$10.9M |
| 2 |
BLU
BELLUS Health Inc.
BLU
|
+$9.84M |
| 3 |
CLSD
Clearside Biomedical
CLSD
|
+$7.9M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$5.75M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$4.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.25% |
| 2 | Financials | 5.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
WHWK
1
Whitehawk Therapeutics
WHWK
$196M
| $36.9M | 15.53% |
1,529,402
| – | – |
|
|
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
| $25.3M | 10.63% |
535,000
+459,500
| +609% | +$18.1M |
|
3
VistaGen Therapeutics
VTGN
$10.1M
| $22.9M | 9.62% |
391,209
+275
| +0.1% | +$17.9K |
|
4
Celldex Therapeutics
CLDX
$2.96B
| $13.1M | 5.52% |
340,098
+2,598
| +0.8% | +$113K |
|
5
GH Research
GHRS
$1.93B
| $9.79M | 4.12% |
419,632
+26,382
| +7% | +$580K |
|
|
6
Relmada Therapeutics
RLMD
$556M
| $9.1M | 3.83% |
+404,000
| New | +$8.98M |
|
|
BLSA
7
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $8.26M | 3.47% |
843,122
| – | – |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.86M | 3.3% |
470,000
-665,000
| -59% | -$10.9M |
|
|
MRUS
9
DELISTED
Merus
MRUS
| $7.49M | 3.15% |
235,500
+113,500
| +93% | +$3.21M |
|
|
10
Pyxis Oncology
PYXS
$193M
| $7.43M | 3.13% |
+677,753
| New | +$7.76M |
|
|
11
Xenon Pharmaceuticals
XENE
$6.02B
| $7.03M | 2.95% |
225,000
-192,409
| -46% | -$5.75M |
|
12
Arrowhead Research
ARWR
$12.1B
| $7M | 2.94% |
105,500
-16,000
| -13% | -$1.1M |
|
|
13
Viridian Therapeutics
VRDN
$2.13B
| $6.29M | 2.64% |
318,000
+182,193
| +134% | +$3.39M |
|
|
JYAC
14
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $5.5M | 2.31% |
562,500
| – | – |
|
15
Syndax Pharmaceuticals
SNDX
$1.7B
| $4.51M | 1.9% |
206,126
| – | – |
|
|
CYT
16
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $4.46M | 1.87% |
391,974
| – | – |
|
|
BLU
17
DELISTED
BELLUS Health Inc.
BLU
| $4.23M | 1.78% |
525,000
-1,482,500
| -74% | -$9.84M |
|
18
Kura Oncology
KURA
$816M
| $4.09M | 1.72% |
291,884
| – | – |
|
|
SEEL
19
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $4.08M | 1.71% |
651
-94
| -13% | -$722K |
|
|
LONA
20
LeonaBio Inc
LONA
$70.2M
| $4.04M | 1.7% |
31,003
+1,267
| +4% | +$160K |
|
21
Orchestra BioMed
OBIO
$247M
| $3.96M | 1.66% |
392,500
| – | – |
|
22
Verastem
VSTM
$500M
| $3.82M | 1.61% |
155,417
-12,786
| -8% | -$404K |
|
23
Fulcrum Therapeutics
FULC
$283M
| $3.54M | 1.49% |
200,000
-122,500
| -38% | -$2.43M |
|
|
24
Iovance Biotherapeutics
IOVA
$1.93B
| $3.44M | 1.44% |
179,995
-194,500
| -52% | -$4.28M |
|
|
ALPN
25
DELISTED
Alpine Immune Sciences Inc
ALPN
| $3.19M | 1.34% |
+230,000
| New | +$2.85M |
|
Similar funds
EC
YEPX
SR
IA
MAM
HA
VVM
KCAM
Acuta Capital Partners's Q4 2021 Portfolio in Review
As of Q4 2021, Acuta Capital Partners held 58 positions worth $238M, down 16% from $283M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Acuta Capital Partners withdrew a net $26.2M in Q4 2021, closing 22 positions and reducing 11 holdings. Its most notable exit was Clearside Biomedical, an estimated $7.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Financials.
Against the trend, Acuta Capital Partners opened a new position in Relmada Therapeutics worth $9.1M.
- Acuta Capital Partners's largest Q4 2021 buy was Relmada Therapeutics: 404,000 shares worth $9.1M.
- Acuta Capital Partners added most to Apellis Pharmaceuticals in Q4 2021, an estimated $18.1M increase.
- Acuta Capital Partners's biggest Q4 2021 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $10.9M.
- Acuta Capital Partners fully exited Clearside Biomedical in Q4 2021, selling an estimated $7.9M.
- Acuta Capital Partners's ten largest holdings make up 62% of its $238M portfolio in Q4 2021.
- Acuta Capital Partners opened 11 new positions and closed 22 in Q4 2021.
- Acuta Capital Partners's portfolio value fell 16% quarter-over-quarter to $238M.
Based on Acuta Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.